Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatology international Mak, L. Y., Hoang, J., Jun, D. W., Chen, C. H., Peng, C. Y., Yeh, M. L., Kim, S. E., Huang, D. Q., Jeong, J. Y., Yoon, E., Oh, H., Tsai, P. C., Huang, C. F., Ahn, S. B., Trinh, H., Xie, Q., Wong, G. L., Enomoto, M., Shim, J. J., Lee, D. H., Liu, L., Kozuka, R., Cho, Y. K., Jeong, S. W., Kim, H. S., Trinh, L., Dao, A., Huang, R., Hui, R. W., Tsui, V., Quek, S., Khine, H. H., Ogawa, E., Dai, C. Y., Huang, J. F., Cheung, R., Wu, C., Chuang, W. L., Lim, S. G., Yu, M. L., Yuen, M. F., Nguyen, M. H. 2021


We aimed to compare the longitudinal changes in estimated glomerular filtration rate (eGFR) in chronic hepatitis B (CHB) patients treated with entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF).This is a retrospective study of 6189 adult treatment-naïve CHB patients initiated therapy with TDF (n?=?2482) or ETV (n?=?3707) at 25 international centers using multivariable generalized linear modeling (GLM) to determine mean eGFR (mL/min/1.73 m2) and Kaplan-Meier method to estimate incidence of renal impairment (=?1 chronic kidney disease [CKD] stage worsening). We also examined above renal changes in matched ETV and TDF patients (via propensity score matching [PSM] on age, sex, diabetes mellitus [DM], hypertension [HTN], cirrhosis, baseline eGFR, and follow-up duration).In the overall cohort (mean age 49.7 years, 66.2% male), the baseline eGFR was higher for TDF vs. ETV group (75.9 vs. 74.0, p?=?0.009). PSM yielded 1871 pairs of ETV or TDF patients with baseline eGFR?=?60 and 520 pairs for the eGFR?

View details for DOI 10.1007/s12072-021-10271-x

View details for PubMedID 34822056